Levothyroxine (LT4) suppression treatment for benign thyroid nodules alters coagulation.
Clin Endocrinol (Oxf)
; 71(3): 446-50, 2009 Sep.
Article
de En
| MEDLINE
| ID: mdl-19138314
ABSTRACT
OBJECTIVE:
Endogenous hyperthyroidism is associated with altered coagulation. The aim of the present study is to investigate the effect of levothyroxine (LT(4)) suppression treatment for benign thyroid nodules on coagulation system.DESIGN:
Prospective case-control study. Patients Thirty consecutive euthyroid pre-menopausal women with nodular goitre disease and 28 healthy controls were included in the study. MEASUREMENTS Plasma fibrinogen, d-dimer, von Willebrand factor (vWF), tissue factor (TF), tissue plasminogen activator (tPA), plasminogen activator inhibitor (PAI-1) and tissue factor pathway inhibitor (TFPI) levels were measured at baseline and after LT(4) suppression therapy.RESULTS:
Plasma levels of fibrinogen, d-dimer, vWF, TF and PAI-1 increased significantly after treatment with LT(4) for 1 year. Serum FT(4) was a significant predictor of increased fibrinogen, vWF and PAI-1 levels, when the data was controlled for age and BMI.CONCLUSIONS:
Our results suggest that LT(4) suppression therapy for benign thyroid nodules is associated with enhanced coagulation.
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Thyroxine
/
Coagulation sanguine
/
Régulation négative
/
Nodule thyroïdien
Type d'étude:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limites:
Adult
/
Female
/
Humans
Langue:
En
Journal:
Clin Endocrinol (Oxf)
Année:
2009
Type de document:
Article
Pays d'affiliation:
Turquie